A case of IgA pemphigus, with a poor response to dapsone, successfully treated with adalimumab
Fig 1: Multiple pustules on an erythematous base with areas of hyperpigmentation in Axilla (A), Groin (B), Left postauricular (C), and the neck.Fig 2: A remarkable response to Adalimumab 40mg/ every two weeks after four months from therapy. Left and right axilla (A)& (B), trunk (C) Key Clinical MessageIgA pemphigus is usually treated by Dapsone. Recalcitrant cases may be treated by Colchicine, Sulfapyridine, or Acitretin. Some patients with recurrent severe disease may not respond to the aforementioned medications. Our study highlights the role of TNFa inhibitor as an alternative modality in the treatment of recalcitra...
Source: Clinical Case Reports - May 15, 2024 Category: General Medicine Authors: Saman Al ‐Zahawi,
Kambiz Kamyab,
Kamran Balighi Tags: CASE REPORT Source Type: research
Association between colchicine use and the risk of dementia among patients with gout: A nationwide retrospective cohort study
ConclusionsA significant risk of dementia was observed in this study in patients with gout using colchicine at higher cDDD and for a longer period. Further research is needed to elucidate the relationship between colchicine, gout, and dementia. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - May 9, 2024 Category: Rheumatology Authors: Pei ‐Yun Chen,
Chu‐Chiao Tseng,
Yi‐Ting Lee,
Hei‐Tung Yip,
Renin Chang,
James Cheng‐Chung Wei Tags: ORIGINAL ARTICLE Source Type: research
Collaborative Study of Thresholds for Mutagens: Adaptive Responses in the Micronucleus Test and Gene Induction by Mutagenic Treatments
CONCLUSION: Adaptive responses arise from preconditioning. As hormesis is inherently linked to preconditioning, adaptive responses observed in this study strongly suggest that hormesis was induced, hence existence of thresholds.PMID:38715588 | PMC:PMC11075607 | DOI:10.1177/15593258241252040 (Source: Dose Response)
Source: Dose Response - May 8, 2024 Category: Drugs & Pharmacology Authors: Shizuyo Sutou Akiko Koeda Kana Komatsu Toshiyuki Shiragiku Hiroshi Seki Toshiyuki Kudo Collaborative Study Group of Thresholds for Mutagens Source Type: research
Collaborative Study of Thresholds for Mutagens: Adaptive Responses in the Micronucleus Test and Gene Induction by Mutagenic Treatments
CONCLUSION: Adaptive responses arise from preconditioning. As hormesis is inherently linked to preconditioning, adaptive responses observed in this study strongly suggest that hormesis was induced, hence existence of thresholds.PMID:38715588 | PMC:PMC11075607 | DOI:10.1177/15593258241252040 (Source: Dose Response)
Source: Dose Response - May 8, 2024 Category: Drugs & Pharmacology Authors: Shizuyo Sutou Akiko Koeda Kana Komatsu Toshiyuki Shiragiku Hiroshi Seki Toshiyuki Kudo Collaborative Study Group of Thresholds for Mutagens Source Type: research
Colchicine for the prevention of atrial fibrillation: Why do some studies say ‘yes’, and others say ‘no’?
Conditions provoking atrial fibrosis and atrial electrical conduction slowing can lead to the development of atrial fibrillation (AF), the most common cardiac arrhythmia [1]. AF risk factors include aging and conditions such as obesity, diabetes, thyroiditis, pulmonary arterial hypertension, or myocardial infarction [2,3,4]. Radiofrequency catheter ablation (RFCA) is a recognized intervention to treat AF [5]. Paradoxically, RFCA is designated among the important causes of postoperative AF (POAF) recurrence [6]. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - May 8, 2024 Category: Cardiology Authors: Abir Attia, Roddy Hiram Source Type: research
Molecules, Vol. 29, Pages 2200: Novel Combretastatin A-4 Analogs & mdash;Design, Synthesis, and Antiproliferative and Anti-Tubulin Activity
In this study, a series of novel combretastatin A-4 analogs containing carboxylic acid, ester, and amide moieties were synthesized and their cytotoxic activity against six tumor cell lines was determined using sulforhodamine B assay. For the most cytotoxic compounds (8 and 20), further studies were performed. These compounds were shown to induce G0/G1 cell cycle arrest in MDA and A549 cells, in a concentration-dependent manner. Moreover, in vitro tubulin polymerization assays showed that both compounds are tubulin polymerization enhancers. Additionally, computational analysis of the binding modes and binding energies of th...
Source: Molecules - May 8, 2024 Category: Chemistry Authors: J ędrzejczyk Morabito Żyżyńska-Granica Struga Janczak Aminpour Jack A. Tuszynski Huczy ński Tags: Article Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026. Online ahead of print.ABSTRACTRoubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.PMID:38710085 | DOI:10.7326/J24-0026 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - May 6, 2024 Category: Internal Medicine Authors: Eric R Bates Source Type: research
Effect of Colchicine Treatment on Clinical Course in Children with
PFAPA Syndrome
Conclusion Colchicine treatment is effective and safe in patients with
PFAPA who have frequent attacks. No association was established between the
presence of heterozygous mutations of MEFV and colchicine response.
Einführung Periodisches Fieber, aphthöse Stomatitis, Pharyngitis und
zervikales Adenitis-Syndrom (PFAPA) ist die häufigste periodische
Fiebererkrankung bei Kindern. Es besteht kein Konsens über die Behandlung, um
Anfällen vorzubeugen und ihre Häufigkeit zu verringern. In dieser Studie wollten
wir die Wirksamkeit der Colchicin-Behandlung beim ...
Source: Klinische Padiatrie - May 6, 2024 Category: Pediatrics Authors: Bagrul, İlknur Aydin, Elif Arslanoglu Tuncez, Serife Baglan, Esra Özdel, Semanur B ülbül, Mehmet Tags: Original Article Source Type: research
Transport of glycinin, the major soybean allergen, across intestinal epithelial IPEC ‐J2 cell monolayers
The objective of this study was to elucidate the pathway and mechanism of glycinin hydrolysate transport through the intestinal epithelial barrier using IPEC-J2 cell model. Purified glycinin was digested by in vitro static digestion model. The pathway and mechanism of glycinin hydrolysates transport through intestinal epithelial cells were investigated by cellular transcytosis assay, cellul ar uptake assay, immunoelectron microscopy and endocytosis inhibition assay. The glycinin hydrolysates were transported across IPEC-J2 cell monolayers in a time/dose-dependent manner following the Michaelis equation. Immunoelectron mi...
Source: Journal of Animal Physiology and Animal Nutrition - May 1, 2024 Category: Zoology Authors: Ziang Zheng,
Yintong Zhao,
Shugui Zheng,
Yajin Liu,
Simiao Liu,
Junfeng Han Tags: ORIGINAL ARTICLE Source Type: research
Po-03-080 low dose colchicine use after atrial fibrillation ablation: short-term results of a randomized, double blinded, placebo controlled trial (colchicine af trial)
Colchicine (C) is used to reduce inflammation and atrial arrhythmia recurrence after atrial fibrillation (AF) ablation, but prior studies have yielded mixed results. (Source: Heart Rhythm)
Source: Heart Rhythm - May 1, 2024 Category: Cardiology Authors: Mohammed Al-Sadawi, Faisal Aslam, Paul M. Kim, Andreas Kalogeropoulos, Chad Gier, Ibrahim O. Almasry, Roger Fan, Eric J. Rashba, Abhijeet Singh Source Type: research
